Chinese medicine preparation compound Huangdai tablet for treating leukemia and its jpreparing method

Abstract

The compound Huangdai tablet as a kind of Chinese medicine preparation for treating acute leukemia, chronic granulocyte leukemia, authentic erythrocytosis, etc. is prepared with realgar 12-18 wt%, natural indigo 25-42 wt%, red sage 36-46 wt% and pseudostellaria root 12-18 wt%. The preparation process includes grinding realgar, natural indigo and pseudostellaria root into fine powder, mixing the fine powder; decocting red sage for 3-5 times, filtering, merging the filtrate, and concentrating at 48-54 deg.c to form extractum of 1.25-1.55 density; adding the red sage extractum into the fine mixed powder, pelletizing, drying, adding magnesium stearate in 1 % to mix homogeneously; pelletizing and tabletting to form 0.25-0.30 g tablet and coating.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine preparations for treating blood diseases and its preparation, in particular to an anti-leukemia traditional Chinese medicine compound Huangdai Tablet and its preparation method, which is used for the main treatment of acute leukemia, chronic myeloid leukemia, polycythemia vera, MDS, Effective treatment of acute promyelocytic leukemia. Background technique [0002] Leukemia is a common and difficult to cure chronic disease. Acute promyelocytic leukemia (acutepromyelocytic Lukemia, APL) is a special type of acute leukemia (acute Lukemia, AL), which is called acute nonlymphocytic leukemia M3 in FAB classification. Type (acute non-lymphacytic Lukemia, ANLL-M3). Its clinical features are extremely easy to be complicated with infection, bleeding and disseminated intravascular coagulation (DIC), and the mortality rate is very high. In 1980, there were two main types of remission in...

AI Technical Summary

Problems solved by technology

In 1980, there were two main types of remission induction treatment for APL at that time: ①Chemotherapy or combined chemotherapy, the complete remission (CR) rate was 60%, but myelosuppression was prone to occur during the course of treatment, resulting in fatal infection, bleeding, and DIC. The mortality rate in the course of treatment can be as high as 30-40%; ② Differentiation-inducing agents, represented by all-trans retinoic acid (ATRA), have a CR rate of 85%, but about 15% of patients still cannot obtain CR. Patients may develop retinoic acid treatment-related syndrome (RS) and rapidly developing drug resistance, with a one-year recurrence rate of over 80%